These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 26905040)

  • 41. Exendin‑4, a glucagon‑like peptide‑1 receptor agonist, modulates hepatic fatty acid composition and Δ‑5‑desaturase index in a murine model of non‑alcoholic steatohepatitis.
    Kawaguchi T; Itou M; Taniguchi E; Sata M
    Int J Mol Med; 2014 Sep; 34(3):782-7. PubMed ID: 24993337
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
    Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
    Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel exendin-4 human serum albumin fusion protein, E2HSA, with an extended half-life and good glucoregulatory effect in healthy rhesus monkeys.
    Zhang L; Wang L; Meng Z; Gan H; Gu R; Wu Z; Gao L; Zhu X; Sun W; Li J; Zheng Y; Dou G
    Biochem Biophys Res Commun; 2014 Mar; 445(2):511-6. PubMed ID: 24565847
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy.
    Perry T; Holloway HW; Weerasuriya A; Mouton PR; Duffy K; Mattison JA; Greig NH
    Exp Neurol; 2007 Feb; 203(2):293-301. PubMed ID: 17125767
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exendin-4 improves the oral glucose tolerance in diabetic rats: pancreas regeneration, better function of pancreatic islets, or impaired glucose uptake?
    Strauss A; Moskalenko V; Chodnevskaja I; Timm S; Thiede A; Otto C; Ulrichs K
    Transplant Proc; 2008 Mar; 40(2):533-5. PubMed ID: 18374122
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preliminary evaluation of [18F]AlF-NOTA-MAL-Cys39-exendin-4 in insulinoma with PET.
    Xu Q; Zhu C; Xu Y; Pan D; Liu P; Yang R; Wang L; Chen F; Sun X; Luo S; Yang M
    J Drug Target; 2015; 23(9):813-20. PubMed ID: 25758750
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glucagon-like peptide-1 receptor agonist activation ameliorates venous thrombosis-induced arteriovenous fistula failure in chronic kidney disease.
    Chien CT; Fan SC; Lin SC; Kuo CC; Yang CH; Yu TY; Lee SP; Cheng DY; Li PC
    Thromb Haemost; 2014 Nov; 112(5):1051-64. PubMed ID: 25030617
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bifunctional PEGylated exenatide-amylinomimetic hybrids to treat metabolic disorders: an example of long-acting dual hormonal therapeutics.
    Sun C; Trevaskis JL; Jodka CM; Neravetla S; Griffin P; Xu K; Wang Y; Parkes DG; Forood B; Ghosh SS
    J Med Chem; 2013 Nov; 56(22):9328-41. PubMed ID: 24144329
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Site-selective modification of exendin 4 with variable molecular weight dextrans by oxime-ligation chemistry for improving type 2 diabetic treatment.
    Dai S; Liu S; Li C; Zhou Z; Wu Z
    Carbohydr Polym; 2020 Dec; 249():116864. PubMed ID: 32933691
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.
    Baggio LL; Huang Q; Cao X; Drucker DJ
    Gastroenterology; 2008 Apr; 134(4):1137-47. PubMed ID: 18313669
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
    Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
    J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
    Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
    Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret.
    Lu Z; Percie Du Sert N; Chan SW; Yeung CK; Lin G; Yew DT; Andrews PL; Rudd JA
    J Transl Med; 2014 Dec; 12():327. PubMed ID: 25491123
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents.
    Egecioglu E; Steensland P; Fredriksson I; Feltmann K; Engel JA; Jerlhag E
    Psychoneuroendocrinology; 2013 Aug; 38(8):1259-70. PubMed ID: 23219472
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preparation and structural, biochemical, and pharmaceutical characterizations of bile acid-modified long-acting exendin-4 derivatives.
    Son S; Chae SY; Kim CW; Choi YG; Jung SY; Lee S; Lee KC
    J Med Chem; 2009 Nov; 52(21):6889-96. PubMed ID: 19827752
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs.
    Chae SY; Jin CH; Shin JH; Son S; Kim TH; Lee S; Youn YS; Byun Y; Lee MS; Lee KC
    J Control Release; 2010 Mar; 142(2):206-13. PubMed ID: 19900495
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Application of novel peptide (Pp1) improving the half-life of exendin-4 in vivo.
    Zheng X; Li Y; Fu G; Gong M
    Peptides; 2011 May; 32(5):964-70. PubMed ID: 21334413
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Persicarin is anti-inflammatory mediator against HMGB1-induced inflammatory responses in HUVECs and in CLP-induced sepsis mice.
    Kim TH; Ku SK; Bae JS
    J Cell Physiol; 2013 Apr; 228(4):696-703. PubMed ID: 22911316
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes.
    Soltani N; Kumar M; Glinka Y; Prud'homme GJ; Wang Q
    Gene Ther; 2007 Jun; 14(12):981-8. PubMed ID: 17410180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.